News Column

Researchers from Kinki University Detail Findings in Rheumatoid Arthritis (Effect of Solid Nanoparticle of Indomethacin on Therapy for Rheumatoid...

August 6, 2014



Researchers from Kinki University Detail Findings in Rheumatoid Arthritis (Effect of Solid Nanoparticle of Indomethacin on Therapy for Rheumatoid Arthritis in Adjuvant-Induced Arthritis Rat)

By a News Reporter-Staff News Editor at Biotech Week -- Data detailed on Autoimmune Diseases have been presented. According to news reporting from Higashiosaka, Japan, by NewsRx journalists, research stated, "We designed new oral formulations containing indomethacin (IMC) solid nanoparticles, and investigate their usefulness by evaluating bioavailability and gastrointestinal lesions. The IMC solid nanoparticles were prepared using methylcellulose (MC), 2-hydroxypropyl-beta-cyclodextrin (HP beta CD),. and the bead mill method, and high quality dispersions containing 1.0% IMC nanoparticles were prepared (IMCnano, particle size: 76 +/- 58 nm, means +/- S.D.)."

The news correspondents obtained a quote from the research from Kinki University, "The fate of serum IMC and the induction of paw edema in adjuvant-induced arthritis (AA) rats receiving low-doses IMCnano. (0.4mg/kg) were similar to those following the administration of a therapeutic dose of conventional IMC prepared with MC and HP beta CD (conventional IMC, 2 mg/kg), and the bioavailability in 0.4 mg/kg IMCnano. was 5.3-fold higher in comparison with that in 2 mg/kg conventional IMC. IMC-induced gastrointestinal lesions in AA rats administered IMCnano (8 mg/kg), in consideration of bioavailability, were significantly less than for conventional IMC (40 mg/kg). On the other hand, the toxicity caused by conventional IMC and IMCnano was similar in Caco-2 cells. It is possible that the oral administration of IMC solid nanoparticles will show increased effectiveness in treating RA without causing IMC-induced gastrointestinal lesions, since the bioavailability is higher than that of conventional IMC."

According to the news reporters, the research concluded: "An oral drug delivery system using drug nanoparticles may expand the usage of NSAIDs for therapy in the inflammatory field."

For more information on this research see: Effect of Solid Nanoparticle of Indomethacin on Therapy for Rheumatoid Arthritis in Adjuvant-Induced Arthritis Rat. Biological & Pharmaceutical Bulletin, 2014;37(7):1109-1118. Biological & Pharmaceutical Bulletin can be contacted at: Pharmaceutical Soc Japan, 2-12-15 Shibuya, Shibuya-Ku, Tokyo, 150-0002, Japan (see also Autoimmune Diseases).

Our news journalists report that additional information may be obtained by contacting N. Nagai, Kinki University, Fac Pharm, Higashiosaka, Osaka 5778502, Japan.

Keywords for this news article include: Asia, Pharmaceuticals, Japan, Drugs, Therapy, Higashiosaka, Indomethacin, Nanoparticle, Joint Diseases, Nanotechnology, Gastroenterology, Autoimmune Diseases, Rheumatoid Arthritis, Emerging Technologies, Musculoskeletal Diseases

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters